Taris Biomedical LLC clinical trials
Acquired by Johnson & Johnson
The registry lists 6 studies whose lead sponsor is Taris Biomedical LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 27, 2024.
Registry sponsor names on this page
- Taris Biomedical LLC5 studies
- TARIS Biomedical, Inc.1 study
Something wrong with this grouping? Tell us on the Johnson & Johnson page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Johnson & Johnson studies →
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminatedNCT03518320Phase 1
Sponsor listed in the registry: Taris Biomedical LLC · Taris Biomedical LLC — acquired company within the Johnson & Johnson group
- Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder CancerCompletedNCT02722538Phase 1
Sponsor listed in the registry: Taris Biomedical LLC · Taris Biomedical LLC — acquired company within the Johnson & Johnson group
- Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder CancerCompletedNCT02720367Phase 1
Sponsor listed in the registry: Taris Biomedical LLC · Taris Biomedical LLC — acquired company within the Johnson & Johnson group
- Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive BladderCompletedNCT03109379Phase 1
Sponsor listed in the registry: Taris Biomedical LLC · Taris Biomedical LLC — acquired company within the Johnson & Johnson group
- Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord InjuryCompletedNCT03168828Phase 1
Sponsor listed in the registry: Taris Biomedical LLC · Taris Biomedical LLC — acquired company within the Johnson & Johnson group
- Safety and Tolerability Study of the Taris Placebo SystemCompletedNCT01051336Phase 1
Sponsor listed in the registry: TARIS Biomedical, Inc. · TARIS Biomedical, Inc. — acquired company within the Johnson & Johnson group